About Medexus Pharmaceuticals
Medexus Pharmaceuticals is a publicly listed company based in Montreal (Canada) founded in 2004 by Ken Dentremont. Pharmaceutical drugs are manufactured for rheumatology, immunology, and oncology sectors. It operates on a Direct-to-Consumer (D2C) model. Medexus Pharmaceuticals has completed 3 acquisitions, including IXINITY, Medac Pharma and Medexus. Its chief executive, as recorded, is Ken Dentremont. Medexus Pharmaceuticals offers products and services including GRAFAPEX (treosulfan) and Specialty Products. Its focus areas include Pharmaceuticals and Specialty Pharmaceuticals. Its legal entity is Medexus Pharmaceuticals, Inc.
Company details
Medexus Pharmaceuticals, Inc. is involved in the distribution of innovative specialty pharmaceutical products across North America. The company operates with a fully integrated infrastructure covering commercial operations, supply chain, regulatory affairs, medical affairs, and salesforce. Its portfolio includes products targeting allergy, dermatology, hematology, oncology, and rheumatology, focusing on rare diseases. Growth is supported by a scalable business model and a strong presence in both Canadian and US markets.
- Headquarters Montreal, Canada
- Founders Ken Dentremont
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website medexus.com/en_US
- Social LinkedIn X
- Legal Name Medexus Pharmaceuticals, Inc.
- Latest Funding Round$55M (USD), Debt – Conventional
Sep 2022
- Investors
- Investments & AcquisitionsIXINITY
& 2 more
Products & Services of Medexus Pharmaceuticals
Medexus Pharmaceuticals offers a comprehensive portfolio of products and services, including GRAFAPEX (treosulfan) and Specialty Products.
Injection used for specific medical treatments in patients.
Products addressing allergy, dermatology, and rare diseases offered.
Funding Insights of Medexus Pharmaceuticals
- Total Rounds 4
- Last Round Debt – Conventional — $55M
- First Round $1.25M
(Mar 2015)
- Investors Count 1
All 4 funding rounds of Medexus Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $55M | Debt – Conventional | – | – | |
| Mar 2020 | $400,000 | Post-IPO | – | – | – |
| Oct 2018 | $62M | Post-IPO | – | – | – |
| Mar 2015 | $1.25M | Debt – Convertible | – | – | – |
1 investors in total: 1 institutional.
Investors in Medexus Pharmaceuticals
Medexus Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MidCap Financial.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States |
Investor details for Medexus Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Medexus Pharmaceuticals
1 people are tracked at Medexus Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ken Dentremont | Founder & CEO | Leadership |
Complete people profiles for Medexus Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Medexus Pharmaceuticals
Medexus Pharmaceuticals is a publicly listed company on the TSX with ticker symbol MDP in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 2021
- Listed onTSX: MDP
- Listed entityMedexus Pharmaceuticals Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Medexus Pharmaceuticals
Medexus Pharmaceuticals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include IXINITY, Medac Pharma and Medexus.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Information on hemophilia B treatment drug is provided by IXINITY. | ixinity.com | Chicago, United States | 2012 | Nov 2020 | •••• | |
Therapeutics for autoimmune diseases and cancer are developed. | medacpharma.com | Chicago, United States | 2012 | Oct 2018 | $50M | |
Develops specialty pharmaceuticals for rare diseases and healthcare needs. | medexus.ca | Mississauga, Canada | 2000 | Sep 2018 | $15M |
Complete acquisition details for Medexus Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Medexus Pharmaceuticals
7 dated milestones of Medexus Pharmaceuticals across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Medexus Pharmaceuticals is founded.
- Funding First funding round of $1.2M.
- Acquisition Acquires Medexus.
- Acquisition Acquires Medac Pharma.
- Acquisition Acquires IXINITY.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $55.0M.
Web traffic of Medexus Pharmaceuticals
The website of Medexus Pharmaceuticals (medexus.com) receives about 6.4K visits a month.
- Monthly visits6.4K
▲ 16.4% vs previous month
Websites whose visitors overlap most with Medexus Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| paragonbiosci.com | 100% | 3.3K | #5,258,376 | View details | |
| xerispharma.com | 93% | 11.8K | #2,449,948 | View details | |
| altathera.com | 92% | 1.2K | #11,742,342 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medexus Pharmaceuticals
Complete news archive for Medexus Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medexus Pharmaceuticals
Medexus Pharmaceuticals was founded in 2004 and raised its 1st funding round 11 years after it was founded.
Medexus Pharmaceuticals is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Ken Dentremont is the CEO of Medexus Pharmaceuticals, as recorded in our data. They have also founded this company.
Medexus Pharmaceuticals, Inc. is involved in the distribution of innovative specialty pharmaceutical products across North America. The company operates with a fully integrated infrastructure covering commercial operations, supply chain, regulatory affairs, medical affairs, and salesforce. Its portfolio includes products targeting allergy, dermatology, hematology, oncology, and rheumatology, focusing on rare diseases. Growth is supported by a scalable business model and a strong presence in both Canadian and US markets.
Medexus Pharmaceuticals offers GRAFAPEX (treosulfan) and Specialty Products.
Yes, Medexus Pharmaceuticals is publicly traded on TSX under the ticker symbol MDP.
Medexus Pharmaceuticals has made 3 acquisitions, including IXINITY, Medac Pharma, and Medexus.
Medexus Pharmaceuticals has 1 investor. Key investors include MidCap Financial.
Medexus Pharmaceuticals operates through Medexus Pharmaceuticals, Inc..